BRIEF—Former Ablynx CEO becomes chair of Virion

The UK’s Virion Biotherapeutics has appointed former Ablynx chief executive Edwin Moses as chairman of the board, replacing Jeffrey Almond.

Dr Moses joined Ablynx in 2004 as chairman and in 2006 became the CEO, a position he held until Ablynx was acquired in 2018 by Sanofi.

Commenting on his appointment, Dr Moses said: “Virion is an exciting biotech company with the potential to revolutionize the treatment of respiratory virus infections, the fourth biggest killer globally.”

“Virion’s first-in-class pipeline is powered by the seasoned Virion team, who are collectively responsible for the development and commercialization of the top selling antiviral agents globally.”